Sign inJoin waitlistJoin the waitlist

Amy Weise

Physician · Henry Ford Health

Credentials: · · · ·

History

Henry Ford Health
2021–Present

Wayne State University School of Medicine
2004–2007
Internal Medicine
1996–1999
Michigan State Univ Coll Osteo Med
1992–1996

Research

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Cancer Discovery · 2020 · 289 citations
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma
British Journal of Cancer · 2021 · 108 citations
A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas
Journal of Clinical Oncology · 2023 · 93 citations

Patricia LoRusso
7 papers
UV
Ulka Vaishampayan
5 papers
HB
Howard Burris
3 papers
JE
Joseph Eder
3 papers
Lawrence Flaherty
3 papers
OR
Olga Radkevich-Brown
3 papers
Aditya Bardia
2 papers
Branimir Sikic
2 papers
David Hong
2 papers
EH
Erika Hamilton
2 papers
Jonathan Goldman
2 papers
Mario Sznol
2 papers

Clinical trials

Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery
Principal investigator · Terminated · Phase 2
Barbara Ann Karmanos Cancer Institute
2010–2017
Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2009–2014
Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer
Principal investigator · Completed · Phase 2
Barbara Ann Karmanos Cancer Institute
2004–2009
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
Site PI · Recruiting · Phase 1, Phase 2
Eikon Therapeutics
2023–2027